Protagonist Therapeutics, Inc. beat EPS estimates 62% of the time across 16 reported quarters (10 beats, 6 misses), averaging +6.2% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $2.11 | $2.29 | +8.5% | Beat | |
| Q1 FY26 | not reported | $0.05 | not reported | not reported | |
| Q4 FY25 | $-0.53 | $-0.69 | -30.2% | Miss | |
| Q3 FY25 | $-0.59 | $-0.62 | -5.1% | Miss | |
| Q2 FY25 | $-0.53 | $-0.55 | -3.8% | Miss | |
| Q1 FY25 | not reported | $-0.19 | not reported | not reported | |
| Q4 FY24 | not reported | $1.98 | not reported | not reported | |
| Q3 FY24 | $-0.59 | $-0.54 | +8.5% | Beat | |
| Q2 FY24 | $-0.50 | $-0.50 | +0.0% | Beat | |
| Q1 FY24 | $2.51 | $3.26 | +29.9% | Beat | |
| Q4 FY23 | not reported | $0.44 | not reported | not reported | |
| Q3 FY23 | $-0.68 | $-0.58 | +14.7% | Beat |
Back to PTGX overview · PTGX holders · PTGX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.